Announcements Trials
Browse Landscape

Phase

Phase 2 19Phase NA 6Phase 1 6Phase 4 5Phase 2/3 4Phase 3 2Phase EARLY_PHASE1 1

Status

Recruiting 5Not yet recruiting 2Completed 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Breast Neoplasms 591Neoplasms 296Carcinoma, Non-Small-Cell Lung 286Prostatic Neoplasms 266Colorectal Neoplasms 213Multiple Myeloma 182Lung Neoplasms 150Neoplasm Metastasis 139Leukemia, Myeloid, Acute 126Leukemia 120Lymphoma 114Lymphoma, Follicular 113Stomach Neoplasms 105Lymphoma, Non-Hodgkin 102Colonic Neoplasms 98Ovarian Neoplasms 96Rectal Neoplasms 95Precursor Cell Lymphoblastic Leukemia-Lymphoma 94Uterine Cervical Neoplasms 93Head and Neck Neoplasms 92Leukemia, Lymphocytic, Chronic, B-Cell 91Pain 90Carcinoma, Hepatocellular 86Pancreatic Neoplasms 81Melanoma 78Lymphoma, Large B-Cell, Diffuse 77Papillomavirus Infections 68Recurrence 66Squamous Cell Carcinoma of Head and Neck 64Parkinson Disease 4, Autosomal Dominant Lewy Body 63

Interventions

midostaurin 1Mercaptopurine 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Completed × Neoplasm, Residual × Clear all
NCT03512197 2023-08-21

A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

Novartis

Phase 3 Completed
511 enrolled 26 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT00816049 2017-04-21

ALL2008con

Rigshospitalet, Denmark

Phase 3 Completed
775 enrolled
LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡